RCM
FLNA

Rotella Capital Management’s Filana Therapeutics FLNA Stock Holding History

Rotella Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,556
Closed -$30K – 138
2013
Q3 		$30K Buy
+1,556
New +$27.2K 0.06% 107

Other funds holding FLNA

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MSP
Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Rotella Capital Management's FLNA Position: Q4 2013 in Review

Rotella Capital Management sold out of Filana Therapeutics (FLNA) in Q4 2013, closing a stake of 1,556 shares — an estimated $30K sold.

Rotella Capital Management first reported a position in FLNA in Q3 2013 and held it in 1 quarter. The position peaked at $30K in Q3 2013. 62 funds tracked by Wall St. Rank hold FLNA as of Q4 2013.

  • Rotella Capital Management reported no remaining Filana Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Rotella Capital Management sold 1,556 Filana Therapeutics shares in Q4 2013, an estimated $30K.
  • Rotella Capital Management first reported a position in Filana Therapeutics in Q3 2013 and held it in 1 quarter.
  • Rotella Capital Management's Filana Therapeutics position peaked at $30K in Q3 2013.
  • 62 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2013.

Based on Rotella Capital Management's 13F filing for Q4 2013, filed 6 Mar 2014.